AR042068A1 - Derivados de antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, sus aplicaciones como medicamentos y los compuestos farmaceuticos que contienen - Google Patents
Derivados de antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, sus aplicaciones como medicamentos y los compuestos farmaceuticos que contienenInfo
- Publication number
- AR042068A1 AR042068A1 ARP030104254A ARP030104254A AR042068A1 AR 042068 A1 AR042068 A1 AR 042068A1 AR P030104254 A ARP030104254 A AR P030104254A AR P030104254 A ARP030104254 A AR P030104254A AR 042068 A1 AR042068 A1 AR 042068A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- radical
- unsubstituted
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Los compuestos de la fórmula (1) en todas sus formas isómeras, solas o en mezcla, así como sus sales de adición fisiológicamente aceptables y así como sus solvatos, en la que G representa: R7R8N-C(=NR6)-NH-CO-; Het-NH-CO-; Het-NH-CH2-; Het-; Het representa un sistema monocíclico o policíclico, estando cada ciclo constituido por 4 a 10 eslabones aromáticos o no aromáticos, teniendo el ciclo, o al menos uno de los ciclos, de 1 a 4 átomos de N, sustituido o no sustituido con uno o más grupos R9; R1 representa un átomo de H, un grupo arilo C5-14, aril (C5-14)-alquilo (C1-4); un radical amino no sustituido o monosustituido o disustituido con un radical alquilo y/o un radical acilo que contienen de 1 a 4 átomos de C; R2 representa un átomo de H, un átomo de halógeno, un grupo nitro, un radical alquilo que contiene de 1 a 4 átomos de C, un radical amino no sustituido o monosustituido o disustituido con un radical alquilo y/o un radical acilo que contienen de 1 a 4 átomos de C, un grupo -(CH2)0-2-CO2R5, o un grupo -(CH2)0-2-OR5; R3 representa: un átomo de H, un radical -CO2R5, un radical -SO2R5 o un sistema monocíclico o policíclico, estando constituido cada ciclo por 4 a 10 eslabones aromáticos o no aromáticos, conteniendo el ciclo, o al menos uno de los ciclos, de 1 a 4 heteroátomos elegidos entre N, O o S, sustituido o no sustituido con uno o mas radicales R9; R4 representa -OH, alcoxi C1-8, aril (C5-14)-alquiloxi(C1-4), ariloxi (C5-14), cicloalquiloxi (C3-12), cicloalquil(C3-12)-alquiloxi(C1-4), alquilcarboniloxi(C1-8)-alquiloxi(C1-4), aril(C5-14)-alquilcarboniloxi(C1-4)-alquiloxi(C1-4), dialquilaminocarbonilmetiloxi(C1-8), aril(C5-14)- dialquilaminocarbonilmetiloxi(C1-4), un radical amino no sustituido o monosustituido o disustituido con un radical alquilo (C1-4) y/o aril(C5-14)-alquilo(C1-4) y/o un radical acilo (C1-5), o bien el resto de un aminoácido D o L; R5 representa alquilo (C1-8), arilo (C5-14), aril(C5-14)-alquilo(C1-4),cicloalquilo (C3-12) o cicloalquil(C3-12)-alquilo(C1-4), bicicloalquil-alquilo(C1-4),triciclo-alquilalquilo (C1-4), estando dichos radicales arilo, alquilo, cicloalquilo, bicicloalquilo y tricicloalquilo sustituidos o no sustituidos con uno o más grupos elegidos de R9; R6 representa un átomo de H, un grupo hidroxilo, nitro, alquil(C1-6)-O-CO-, o alquil(C1-6)-O-CO-O-; R7 y R8, independientemente entre sí representan un átomo de H o un radical alquilo (C1-6) no sustituido o sustituido con R9; R9 representa halógeno, amino, nitro, hidroxilo, alquiloxi(C1-4),alquiltio (C1-4), carboxi, alquiloxicarbonilo (C1-4), alquilo(C1-8) no sustituido o sustituido con uno o más átomos de halógeno, arilo (C5-14), aril(C5-14)-alquilo(C1-4), entendiéndose que los radicales arilo pueden estar sustituidos o no sustituidos con uno o más radicales idénticos o diferentes elegido entre alquilo (C1-8), en particular alquilo (C1-4), hidroxilo, alquiloxi (C1-8), alquiltio (C1-8), halógeno elegido entre F, Cl, y Br, nitro, amino, alquilamino (C1-4), dialquilamino (C1-4), trifluorometilo, metilendioxi, ciano, aminocarbonilo, alquilaminocarbonilo (C1-4), dialquilaminocarbonilo (C1-4), carboxi, alcoxicarbonil(C1-4), fenilo, fenoxi, bencilo y benciloxi o G representa 1,2,3,4-tetrahidro-1,8-naftiridin-7-il, R1 representa metil, R2 representa metil, R3 representa fenilmetoxicarbonil y R4 representa -OH o t.butoxi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0214429A FR2847254B1 (fr) | 2002-11-19 | 2002-11-19 | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042068A1 true AR042068A1 (es) | 2005-06-08 |
Family
ID=32187700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104254A AR042068A1 (es) | 2002-11-19 | 2003-11-18 | Derivados de antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, sus aplicaciones como medicamentos y los compuestos farmaceuticos que contienen |
| ARP100102568A AR077476A2 (es) | 2002-11-19 | 2010-07-15 | Derivados antagonistas del receptor de la vitronectina, procedimiento de preparacion, composiciones farmaceuticas y usos de los compuestos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102568A AR077476A2 (es) | 2002-11-19 | 2010-07-15 | Derivados antagonistas del receptor de la vitronectina, procedimiento de preparacion, composiciones farmaceuticas y usos de los compuestos |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7582640B2 (es) |
| EP (2) | EP1565467B1 (es) |
| JP (1) | JP4567459B2 (es) |
| KR (1) | KR101140752B1 (es) |
| CN (2) | CN101928287A (es) |
| AR (2) | AR042068A1 (es) |
| AT (2) | ATE431825T1 (es) |
| AU (2) | AU2003299330B2 (es) |
| BR (1) | BR0316307A (es) |
| CA (1) | CA2506310C (es) |
| CO (1) | CO5700761A2 (es) |
| CY (1) | CY1112218T1 (es) |
| DE (1) | DE60327712D1 (es) |
| DK (2) | DK2070914T3 (es) |
| ES (2) | ES2325616T3 (es) |
| FR (1) | FR2847254B1 (es) |
| HK (2) | HK1076277A1 (es) |
| IL (2) | IL168136A (es) |
| MA (1) | MA27492A1 (es) |
| MX (1) | MXPA05005340A (es) |
| NO (1) | NO20052491D0 (es) |
| PL (1) | PL376866A1 (es) |
| PT (2) | PT2070914E (es) |
| RU (1) | RU2412185C2 (es) |
| SI (2) | SI2070914T1 (es) |
| TW (1) | TW200412969A (es) |
| WO (1) | WO2004048375A1 (es) |
| ZA (1) | ZA200502850B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2847254B1 (fr) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
| FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| US20110189174A1 (en) * | 2010-02-01 | 2011-08-04 | Afshin Shafiee | Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization |
| US20110237605A1 (en) | 2010-03-26 | 2011-09-29 | Eric Phillips | Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative |
| AU2019326932A1 (en) | 2018-08-17 | 2021-03-18 | Oxurion NV | Integrin antagonists |
| WO2021165206A1 (en) | 2020-02-19 | 2021-08-26 | Oxurion NV | Treatment of dry amd with integrin antagonists |
| WO2022005933A1 (en) | 2020-06-29 | 2022-01-06 | Ickovic & Bliss, Inc. | Systems, methods, and program products for digital pet identification |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
| US5204350A (en) | 1991-08-09 | 1993-04-20 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives |
| EP0667773A4 (en) | 1992-10-14 | 1996-09-25 | Merck & Co Inc | FIBRINOGEN RECEPTOR ANTAGONISTS. |
| WO1994012181A1 (en) | 1992-12-01 | 1994-06-09 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH10501222A (ja) | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
| JPH10504807A (ja) * | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
| CZ382496A3 (en) | 1994-06-29 | 1997-12-17 | Smithkline Beecham Corp | Compounds representing antagonists of vitronectin receptors, process of their preparation, intermediates of such process, pharmaceutical composition containing the compounds and their use |
| PL330915A1 (en) | 1996-06-28 | 1999-06-07 | Merck Patent Gmbh | Phenylaniline derivatives as inhibitors of integrin |
| DE19629816A1 (de) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| US6723727B1 (en) * | 1996-12-20 | 2004-04-20 | Hoechst Aktiengesellschaft | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
| DE19653646A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
| EP0933367A1 (en) * | 1997-12-19 | 1999-08-04 | Hoechst Marion Roussel Deutschland GmbH | Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists |
| TR200002160T2 (tr) | 1998-01-23 | 2001-07-23 | Aventis Pharma Deutschland Gmbh | Yeni sülfonamid türevleri |
| CA2333927A1 (en) * | 1998-04-01 | 1999-10-07 | Dupont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
| EP1102587A4 (en) * | 1998-08-07 | 2003-03-12 | Smithkline Beecham Corp | vitronectin receptor antagonists |
| AU748949B2 (en) | 1999-06-23 | 2002-06-13 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP1065207A1 (en) | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| EP1065208A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
| ATE248646T1 (de) * | 1999-10-05 | 2003-09-15 | Element Six Pty Ltd | Wachstum von diamantclustern |
| DE10042655A1 (de) | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion |
| FR2847254B1 (fr) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
| FR2870541B1 (fr) * | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
-
2002
- 2002-11-19 FR FR0214429A patent/FR2847254B1/fr not_active Expired - Fee Related
-
2003
- 2003-11-12 DK DK09003174.1T patent/DK2070914T3/da active
- 2003-11-12 PT PT09003174T patent/PT2070914E/pt unknown
- 2003-11-12 SI SI200332048T patent/SI2070914T1/sl unknown
- 2003-11-12 AT AT03799611T patent/ATE431825T1/de active
- 2003-11-12 DK DK03799611T patent/DK1565467T3/da active
- 2003-11-12 PL PL376866A patent/PL376866A1/pl not_active Application Discontinuation
- 2003-11-12 BR BR0316307-5A patent/BR0316307A/pt not_active IP Right Cessation
- 2003-11-12 AT AT09003174T patent/ATE518842T1/de active
- 2003-11-12 EP EP03799611A patent/EP1565467B1/fr not_active Expired - Lifetime
- 2003-11-12 DE DE60327712T patent/DE60327712D1/de not_active Expired - Lifetime
- 2003-11-12 WO PCT/FR2003/003349 patent/WO2004048375A1/fr active Application Filing
- 2003-11-12 EP EP09003174A patent/EP2070914B1/fr not_active Expired - Lifetime
- 2003-11-12 KR KR1020057009101A patent/KR101140752B1/ko active IP Right Grant
- 2003-11-12 CN CN2009101705723A patent/CN101928287A/zh active Pending
- 2003-11-12 US US10/536,028 patent/US7582640B2/en active Active
- 2003-11-12 SI SI200331636T patent/SI1565467T1/sl unknown
- 2003-11-12 PT PT03799611T patent/PT1565467E/pt unknown
- 2003-11-12 CA CA2506310A patent/CA2506310C/fr not_active Expired - Lifetime
- 2003-11-12 MX MXPA05005340A patent/MXPA05005340A/es active IP Right Grant
- 2003-11-12 AU AU2003299330A patent/AU2003299330B2/en not_active Ceased
- 2003-11-12 ES ES03799611T patent/ES2325616T3/es not_active Expired - Lifetime
- 2003-11-12 RU RU2005119163/04A patent/RU2412185C2/ru not_active Application Discontinuation
- 2003-11-12 CN CN2003801088984A patent/CN1738817B/zh not_active Expired - Fee Related
- 2003-11-12 ES ES09003174T patent/ES2369561T3/es not_active Expired - Lifetime
- 2003-11-12 JP JP2004554592A patent/JP4567459B2/ja not_active Expired - Fee Related
- 2003-11-13 TW TW092131850A patent/TW200412969A/zh unknown
- 2003-11-18 AR ARP030104254A patent/AR042068A1/es unknown
-
2005
- 2005-04-07 ZA ZA200502850A patent/ZA200502850B/en unknown
- 2005-04-19 IL IL168136A patent/IL168136A/en active IP Right Grant
- 2005-05-12 MA MA28281A patent/MA27492A1/fr unknown
- 2005-05-16 CO CO05046617A patent/CO5700761A2/es not_active Application Discontinuation
- 2005-05-23 NO NO20052491A patent/NO20052491D0/no not_active Application Discontinuation
- 2005-11-03 HK HK05109816.8A patent/HK1076277A1/xx not_active IP Right Cessation
-
2008
- 2008-10-03 US US12/245,622 patent/US7763621B2/en not_active Expired - Fee Related
-
2009
- 2009-07-03 HK HK09106005.1A patent/HK1129372A1/xx not_active IP Right Cessation
- 2009-08-24 AU AU2009212779A patent/AU2009212779B2/en not_active Ceased
-
2010
- 2010-05-11 IL IL205693A patent/IL205693A/en active IP Right Grant
- 2010-07-15 AR ARP100102568A patent/AR077476A2/es not_active Application Discontinuation
-
2011
- 2011-11-02 CY CY20111101051T patent/CY1112218T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| UY28122A1 (es) | Nuevos derivados de fluoroglicósidos heterocíclicos, medicamentos que contienen estos compuestos, y el uso de los mismos. | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| UY29177A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| AR033594A1 (es) | Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR056686A1 (es) | Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas | |
| UY32978A (es) | Derivados de la cromenona | |
| NO20022857D0 (no) | Nye P2X7-reseptoragonister for bruk i behandling av inflammatoriske, immune eller kardiovaskul¶re sykdommer | |
| AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
| AR049398A1 (es) | Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados. | |
| AR012593A1 (es) | Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento | |
| AR066659A1 (es) | Derivados de espiroindolinona | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| CY1113482T1 (el) | Αναστολεις υποδοχεα σιγμα | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
| AR044586A1 (es) | Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion | |
| AR039601A1 (es) | Derivados de nitrosodifenilamina y composiciones farmaceuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologias que se caracterizan por estres oxidativo | |
| PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| DOP2011000019A (es) | Nuevos derivados de imidazo [1,2-a] pirimidina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |